A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Cataract Clinical Trial

Official title:

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06383273
• Other study ID #: MELT-3-001
• Status: Recruiting
• Phase: Phase 3
• Start date: May 1, 2024
• Est. completion date: January 2025

Study information

• Verified date: May 2024
• Source: Melt Pharmaceuticals
• Contact: Giovanni DeCastro
• Phone: 6157670074
• Email: gdecastro[@]meltpharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the safety of MELT-300. Researchers will compare MELT-300 to a placebo (a look-alike substance that contains no drug) to see if MELT-300 works on procedural sedation in adult participants undergoing CELR. Researchers will also include a comparator SL midazolam to confirm the benefit of inclusion of ketamine in the combined drug product.

The main questions it aims to answer are:

1. Does MELT-300 is effective in comparison to placebo on procedural sedation for cataract surgery?

2. To determine the effectiveness of MELT-300 compared with midazolam on procedural sedation (to determine the contribution of ketamine component and inform the risk of ketamine in MELT-300)

3. To determine the time to achieve preoperative target sedation level with MELT-300

4. What medical problems do participants have when taking MELT-300 vs placebo

Eligible participants will admitted to the study unit on Day 1. Participants will be randomized prior to surgery 4:1:1 to

1. MELT-300 (i.e. 1 MELT-300 sublingual tablet which contains 3 mg midazolam and 50 mg of ketamine)

2. Midazolam (i.e. 1 matching midazolam sublingual tablet which contains 3 mg midazolam)

3. Placebo (i.e. 1 matching placebo sublingual tablet)

Participants will receive study medication 30 (± 5) minutes, without food or water, before planned surgery start (defined as instillation of topical ocular anesthetic gel [i.e.. 3 drops of chloroprocaine hydrochloride ophthalmic gel)].

The effectiveness of MELT-300 will be performed after study medication is administered before surgery, in the course of surgery, and postoperative on Day 1 (end of surgery defined as just prior to drape removal). The safety of MELT-300 will be performed at baseline, in the course of surgery, postoperatively on Day 1, and on Day 3 ± 1 day post dose of study medication.

Description:

This is a Phase 3, randomized, double-masked, placebo-controlled, parallel-cohort, multicenter study to evaluate the efficacy and safety of MELT-300 compared with placebo on procedural sedation in adult participants undergoing CELR. An active comparator, SL midazolam, is also included in the trial, in part, to confirm the benefit of inclusion of ketamine in the combined drug product.

Approximately 486 participants will be enrolled in 3 parallel treatment arms to assess efficacy endpoints.

Eligible participants will be admitted to the study unit on Day 1. Participants will be randomized prior to surgery 4:1:1 to

1. MELT-300 (i.e. 1 MELT-300 sublingual tablet which contains 3 mg midazolam and 50 mg of ketamine)

2. Midazolam (i.e. 1 matching midazolam sublingual tablet which contains 3 mg midazolam)

3. Placebo (i.e. 1 matching placebo sublingual tablet) Participants will receive study medication 30 (± 5) minutes, without food or water, before planned surgery start (defined as instillation of topical ocular anesthetic gel [i.e.. 3 drops of chloroprocaine hydrochloride ophthalmic gel)].

Efficacy assessments will be performed after study medication administration before surgery, intraoperatively, and postoperative on Day 1 (end of surgery defined as just prior to drape removal). Efficacy assessments will include assessments of sedation, need for rescue medication for sedation, need for rescue medication for pain, and the ability to complete the surgery.

Safety will be monitored at baseline, intraoperatively, postoperatively on Day 1, and on Day 3 ± 1 day post dose of study medication. Safety assessment will include monitoring of AEs, vital sign measurements, and physical examinations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 486
• Est. completion date: January 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Participants must meet all of the following in order to be enrolled into the study:

1. Males and females = 18 years of age

2. Are to undergo unilateral primary CELR under topical anesthesia, with a phacoemulsification device and insertion of an intraocular lens

3. For women of childbearing potential (WOCBP), have a negative urine pregnancy test, and abstain from sexual activity or use a double barrier method (e.g. condom and diaphragm) of birth control from Day 1 and up to 2 days after study drug administration.

4. Willing to refrain from alcohol consumption within 24 hours of randomization

5. Are competent to provide informed consent

6. Voluntarily provide informed consent in accordance with governing International Review Board (IRB) requirements and provide Health Insurance Portability and Accountability Act (HIPAA) authorization, prior to any procedures or evaluations performed specifically for the sole purpose of the study

7. Indicate they understand and are able, willing, and likely to fully comply with study procedures and restrictions

Exclusion Criteria:

1. Subjects scheduled for simultaneous bilateral or 2nd-eye cataract surgery (subjects scheduled for a future 2nd eye cataract surgery are eligible for the study)

2. Known sensitivity to benzodiazepines or ketamine

3. Known sensitivity to -caines (including proparacaine, ester-type local anesthetics), benzalkonium chloride (BAK)

4. Intraocular pressure (IOP) > 30 mmHg in the study eye or fellow eye at screening.

5. History of iritis, or any ocular trauma with iris damage in the study eye

6. Presence of active corneal pathology other than dry eye per slit lamp and external eye exam at screening in either eye

7. Presence of extraocular/intraocular inflammation in either eye

8. Presence of active bacterial and/or viral infection in either eye

9. History of intraocular non-laser surgery in the study eye within the 3 months prior to day of surgery, or intraocular laser surgery in the study eye within 30 days prior to the day of surgery

10. Requiring or planning other additional ocular surgery during the cataract surgery (e.g. glaucoma surgery ([minimally invasive or traditional], limbal relaxing incisions, etc.) or performing laser-assisted CELR

11. Presence of active infection, mucositis, cold sores, canker sores, vesicles, viral lesions, local irritation/inflammation, or periodontal disease of the oral cavity. In addition, evidence of piercings of the tongue or anywhere in the oral cavity, history of oral cavity piercings, history of significant dental disease, or history of dysphagia.

12. Women who are nursing a child or plan to nurse a child during the study

13. Have a history or clinical manifestations (e.g., signs, symptoms, laboratory values, diagnostic imaging, etc.) of significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that in the opinion of the investigator might confound the study results or pose additional risk in administering the study procedures

14. Use of disallowed medications including the following:

1. Antihypertensive agent or diabetic regimen at a dose that has not been stable for at least 30 days prior to Day 1, or which is not expected to remain stable throughout the study

2. Central nervous system (CNS) active drugs such as benzodiazepines, tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors (SNRIs), or selective serotonin reuptake inhibitors (SSRIs) that have not been stable for at least 30 days prior to Day 1, or which is not expected to remain stable throughout the study

3. Initiating the use of, switching to a different, or increasing the dose of a sleep medication (e.g. lorazepam, zolpidem, etc) within 3 days of randomization

15. Illicit drug use (including marijuana) or alcohol abuse based on medical history, or currently engaged in illicit drug use or alcohol abuse.

1. Alcohol abuse is defined as 5 or more drinks in one sitting or 15 or more drinks in a week for men and 4 or more drinks in one sitting or 8 or more drinks in a week for women. A drink is considered a 1.5 oz shot, 12 oz of beer, or 5 oz of wine.

2. However, patients with a medical history of illicit drug use or alcohol abuse = 5 years prior to the time of screening and who have recovered and have been drug/alcohol free for at least that period of time (i.e., 5 years) can be enrolled

16. Creatinine clearance rate < 60 mL/min estimated using the Cockroft-Gault formula

17. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) > 2.5 times upper limit of normal (ULN), or total bilirubin > 1.5 x ULN. In cases of documented Gilbert syndrome, subjects with elevated bilirubin levels will be permitted to enroll in the study if other liver function tests are within the specified limits

18. Any other abnormal laboratory results or presence of any condition that the Investigator believes would put the subject at risk or confound the interpretation of results

Related Conditions & MeSH terms

• Cataract

Intervention

Drug:
• MELT-300 sublingual tablet
Each dose of MELT-300 will be provided as a single sublingual tablet, containing 3 mg midazolam and 50 mg ketamine. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
• Midalozam sublingual tablet
Each dose of midazolam will be provided as a single sublingual tablet, containing 3 mg midazolam. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
• Placebo sublingual tablet
Each dose of placebo will be provided as a matching sublingual tablet, containing placebo. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.

Locations

Country	Name	City	State
United States	Vance Thompson Vision- Alexandria	Alexandria	Minnesota
United States	Tekwani Vision Center	Bay Saint Louis	Mississippi
United States	Ridge Eye Care, Inc.	Chico	California
United States	Conway Ophthalmology	Conway	South Carolina
United States	Bergstrom Eye Research	Fargo	North Dakota
United States	Icon Eye Care	Grand Junction	Colorado
United States	Maryland Vision Institute	Hagerstown	Maryland
United States	Levenson Eye Associates	Jacksonville	Florida
United States	Utah Eye Centers- Pleasant Grove	Pleasant Grove	Utah
United States	Northeastern Eye Institute	Scranton	Pennsylvania
United States	Vance Thompson Vision	Sioux Falls	South Dakota
United States	Vance Thompson Vision, ND	W. Fargo	North Dakota

Sponsors (5)

Lead Sponsor	Collaborator
Melt Pharmaceuticals	Catalent, Evolution Research Group, MedTrials Incorporated, Pharmalex

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Achieving Successful Procedural Sedation	Successful procedural sedation is defined as achieving target sedation level (Ramsay Sedation Scale [RSS] level 2 or 3) by the start of surgery without need for rescue sedation medication, no requirement for intraoperative sedation medication, and able to complete the surgery (i.e. procedural sedation responder). The Ramsay Sedation Scale (RSS) was the first scale to be defined for the sedated participants and was designed as a test of arousability. The Ramsay Scale provides three levels of 'awake' states (score 1-3) and three levels of 'asleep' states (score 4-6). A score of 2 (participant is cooperative, orientated, and tranquil) best fits an optimum sedation level based on the criteria of calm, comfortable, communicative, and cooperative participants.	Preoperative (Day 1), Intraoperative (Day 1), and Postoperative (Day 1)
Secondary	Percentage of Participants Requiring Rescue Sedation Medication	Rescue sedation medication (i.e., intravenous midazolam) at a dose determined by Investigator or anesthesiologist may be given. Use of rescue sedation medication during surgery will be allowed if a participant's RSS score is < 2.	Preoperative (Day 1) and Intraoperative (Day 1)
Secondary	Percentage of Participants Achieving Preoperative Procedural Sedation Without Need For Rescue Sedation Medication	Participants achieving target sedation level RSS level 2 or 3 by the start of surgery without need for rescue sedation medication.	Preoperative (Day 1)
Secondary	Percentage of Participants Requiring Rescue Sedation Medication Preoperatively	Rescue sedation medication (i.e., intravenous midazolam) at a dose determined by Investigator or anesthesiologist may be given. Use of rescue sedation medication during surgery will be allowed if a participant's RSS score is < 2.	Preoperative (Day 1)
Secondary	Percentage of Participants Requiring Rescue Sedation Medication Intraoperatively	Rescue sedation medication (i.e., intravenous midazolam) at a dose determined by Investigator or anesthesiologist may be given. Use of rescue sedation medication during surgery will be allowed if a participant's RSS score is < 2.	Intraoperative (Day 1)
Secondary	Assessment of Sedation Scores in Participants Without Requiring Rescue Sedation Medication	Target sedation level (RSS level 2 or 3) by the start of surgery without need for rescue sedation medication, no requirement for intraoperative sedation medication, and able to complete the surgery (i.e. procedural sedation responder).	Preoperative (Day 1), Intraoperative (Day 1), and Postoperative (Day 1)
Secondary	Percentage of Participants Able to Complete the Surgery	Participants achieving the target sedation level (RSS level 2 or 3) by the start of surgery without need for rescue sedation medication, no requirement for intraoperative sedation medication.	Postoperative (Day 1)
Secondary	Percentage of Participants Able to Complete the Surgery Without Intervention (Other Than Rescue Sedation Medication)		Postoperative (Day 1)
Secondary	Duration to Achieve Preoperative Target Sedation (RSS level 2 or 3)	Measurement of duration (time taken) to achieve target sedation level (RSS level 2 or 3) by the start of surgery.	Preoperative (Day 1)
Secondary	Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	An adverse event is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.	Baseline, Preoperative (Day 1), Intraoperative (Day 1), Postoperative (Day 1), and Day 3 ± 1 post dose of study medication
Secondary	Percentage of Participants Reporting Adverse Events Special Interest (AESIs)	The prespecified AESI include: AEs representing ketamine emergence delirium (i.e.., hallucinations, unpleasant/bad dreams, vivid imagery, confusional state, excitement, behavior abnormal, agitation),; Respiratory AEs (i.e.., respiratory depression, hypoventilation, dyspnea, oxygen desaturation, respiratory arrest, airway obstruction),; Cardiovascular AEs (i.e.., hypotension, blood pressure increased, hypertension [new onset or worsened], bradycardia/tachycardia, cardiac arrest, cardiac decompensation),; Neurocognitive AEs (i.e.., confusional state, amnesia, memory impairment, attention impaired, disorientation, delirium).; Abuse-related AEs; Oversedation (i.e.. sedation excessive) requiring the use of flumazenil; Oral/pharyngeal AEs (i.e.. changes to tongue, oral cavity [active infection, mucositis, cold sores, canker sores, vesicles, viral lesions, stomatitis, periodontal disease], and/or oral/pharyngeal function [hypoesthesia, taste disorders, dysphagia])	Baseline, Preoperative (Day 1), Intraoperative (Day 1), Postoperative (Day 1), and Day 3 ± 1 post dose of study medication
Secondary	Mean Change from Baseline in Blood Pressure (mmHg)		Baseline, Preoperative (Day 1), Intraoperative (Day 1), Postoperative (Day 1), and Day 3 ± 1 post dose of study medication
Secondary	Mean Change from Baseline in Heart Rate [beats per minute (bpm)]		Baseline, Preoperative (Day 1), Intraoperative (Day 1), Postoperative (Day 1), and Day 3 ± 1 post dose of study medication
Secondary	Mean Change from Baseline in Respiratory Rate (breath per minute)		Baseline, Preoperative (Day 1), Intraoperative (Day 1), Postoperative (Day 1), and Day 3 ± 1 post dose of study medication
Secondary	Mean Change from Baseline in Body Temperature (degrees Fahrenheit)		Baseline, Preoperative (Day 1), Intraoperative (Day 1), Postoperative (Day 1), and Day 3 ± 1 post dose of study medication
Secondary	Mean Change from Baseline in Pulse Oximetry (%)		Baseline, Preoperative (Day 1), Intraoperative (Day 1), Postoperative (Day 1), and Day 3 ± 1 post dose of study medication